FY2025 · ended Dec 31, 2025 · Revenue $184.42M, +404.5% YoY · Filed Mar 16, 2026
Stoke Therapeutics, Inc. (STOK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $184.4 million and a net loss of $6.9 million. Free cash flow was $44.9 million. As of Sep 30, 2026 it held $358.8 million in cash and investments and $1.9 million in total debt.
Revenue (TTM)
$28.21M
-86.3% vs year-ago TTM
Net income (TTM)
$-243.20M
-699.5% vs year-ago TTM
Operating cash flow (TTM)
$-210.31M
-498.0% vs year-ago TTM
Free cash flow (TTM)
$-215.72M
-511.9% vs year-ago TTM
EPS (TTM)
$-3.84
-664.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
59.15M
+9.4% vs prior year
Net cash
$356.87M
as of Sep 30, 2026
Operating margin
-913.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- STOK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1623526
- Former names
- ASOthera Pharmaceuticals, Inc. (until Nov 24, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M |
| Diluted EPS | -$0.12 | -$1.65 | -$2.38 | -$2.60 | — |
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M |
| Stockholders' equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M |
| Cash and investments | $390.9M | $246.7M | $201.4M | $229.6M | $219.8M |
| Total debt | $4.1M | $4.8M | $6.8M | $5.1M | $7.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 25, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Other events
|
Aug 3, 2026 | Aug 3, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
All 632 Stoke Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.